Viewing Study NCT03330561

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 12:05 PM
Ignite Modification Date: 2026-02-25 @ 4:56 PM
Study NCT ID: NCT03330561
Status: COMPLETED
Last Update Posted: 2024-04-22
First Post: 2017-10-19
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: PRS-343 in HER2-Positive Solid Tumors
Sponsor: Pieris Pharmaceuticals, Inc.
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None HER2-positive Breast Cancer View
None HER2-positive Gastric Cancer View
None HER2-positive Bladder Cancer View
None HER2-positive Solid Tumor View
Keywords:

Keywords

Keyword Brief Keyword Text View
None HER2 View
None HER2-positive breast cancer View
None HER2 -positive gastric cancer View
None HER2-positive bladder cancer View
None Pieris View
None PRS-343 View
None Anticalin View
None Bi-specific View
None 4-1BB View
None CD137 View